CA2090957A1 - Anti-tumor method and anti-tumor agent - Google Patents

Anti-tumor method and anti-tumor agent

Info

Publication number
CA2090957A1
CA2090957A1 CA002090957A CA2090957A CA2090957A1 CA 2090957 A1 CA2090957 A1 CA 2090957A1 CA 002090957 A CA002090957 A CA 002090957A CA 2090957 A CA2090957 A CA 2090957A CA 2090957 A1 CA2090957 A1 CA 2090957A1
Authority
CA
Canada
Prior art keywords
cells
tumor
antigen
mice
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002090957A
Other languages
English (en)
French (fr)
Inventor
Kohji Egawa
Ichiei Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIO DEFENCE INSTITUTE Co Ltd
Original Assignee
BIO DEFENCE INSTITUTE CO., LTD.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIO DEFENCE INSTITUTE CO., LTD. filed Critical BIO DEFENCE INSTITUTE CO., LTD.
Publication of CA2090957A1 publication Critical patent/CA2090957A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002090957A 1992-03-05 1993-03-03 Anti-tumor method and anti-tumor agent Abandoned CA2090957A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4048840A JPH05246889A (ja) 1992-03-05 1992-03-05 制癌方法および制癌剤
JP4-48840 1992-03-05

Publications (1)

Publication Number Publication Date
CA2090957A1 true CA2090957A1 (en) 1993-09-06

Family

ID=12814449

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002090957A Abandoned CA2090957A1 (en) 1992-03-05 1993-03-03 Anti-tumor method and anti-tumor agent

Country Status (15)

Country Link
EP (1) EP0563627A2 (enExample)
JP (1) JPH05246889A (enExample)
KR (1) KR930019225A (enExample)
CN (1) CN1079400A (enExample)
AU (1) AU3398793A (enExample)
BR (1) BR9300764A (enExample)
CA (1) CA2090957A1 (enExample)
CZ (1) CZ34293A3 (enExample)
FI (1) FI930976L (enExample)
HU (1) HUT67859A (enExample)
IL (1) IL104944A0 (enExample)
NO (1) NO930798L (enExample)
NZ (1) NZ247057A (enExample)
SK (1) SK15993A3 (enExample)
ZA (1) ZA931558B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
IT1274592B (it) * 1994-08-05 1997-07-18 Angela Turiano Composizione farmaceutica per la terapia tumorale contenente xenoantigeni
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
WO1998019167A2 (en) * 1996-10-29 1998-05-07 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
ES2224603T3 (es) * 1998-02-20 2005-03-01 Commissariat A L'energie Atomique Procedimiento de seleccion de tumores que expresan hla-g sensibles a un tratamiento anticanceroso y sus aplicaciones.
FR2775189B1 (fr) * 1998-07-24 2001-06-08 Commissariat Energie Atomique Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
EP1245675A1 (en) * 2001-03-28 2002-10-02 Kohji Egawa Cancer cell-specific HLA-F antigen and a diagnostic method of cancer by using thereof
WO2004078137A2 (en) * 2003-03-04 2004-09-16 Greenville Hospital System Antitumor agents comprising a targeting portion and an immune response triggering portion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung

Also Published As

Publication number Publication date
JPH05246889A (ja) 1993-09-24
ZA931558B (en) 1993-09-27
CN1079400A (zh) 1993-12-15
HUT67859A (en) 1995-03-23
IL104944A0 (en) 1993-07-08
BR9300764A (pt) 1993-09-28
KR930019225A (ko) 1993-10-18
FI930976A0 (fi) 1993-03-04
FI930976A7 (fi) 1993-09-06
NO930798L (no) 1993-09-06
AU3398793A (en) 1993-09-09
NO930798D0 (no) 1993-03-04
EP0563627A2 (en) 1993-10-06
NZ247057A (en) 1995-10-26
SK15993A3 (en) 1993-10-06
HU9300612D0 (en) 1993-05-28
FI930976L (fi) 1993-09-06
EP0563627A3 (enExample) 1994-04-27
CZ34293A3 (en) 1994-01-19

Similar Documents

Publication Publication Date Title
ES2258772T3 (es) Redireccion de la inmunidad celular por quimeras de proteina-tirosina quinasa.
ES2245456T3 (es) Redireccion de la inmunidad celular por quimeras de receptores.
KR101507976B1 (ko) 종양에서 특이적으로 발현되는 유전 산물 및 그의 용도
Koch-Nolte et al. A new monoclonal antibody detects a developmentally regulated mouse ecto-ADP-ribosyltransferase on T cells: subset distribution, inbred strain variation, and modulation upon T cell activation
RU2161044C2 (ru) Способ направления (индукции) иммунного ответа, днк, вектор, способ лечения
ES2315016T3 (es) Moleculas llamadas b7l-1.
KR100748920B1 (ko) 단백분해 항체의 유도제 및 억제제를 동정하는 방법,조성물 및 이들의 용도
EP1301605B1 (en) Nk cells activating receptors and their therapeutic and diagnostic uses
EP1790728B1 (en) Imaging, diagnosis and treatment of disease
JP2001510987A (ja) 哺乳動物のＣＤ９７αサブユニットを含む炎症および脈管形成を阻害するための方法および組成物
AU2001278662A1 (en) NK cells activating receptors and their therapeutic and diagnostic uses
ES2197166T3 (es) Redireccion de la inmunidad celular por receptores quimericos.
CA2090957A1 (en) Anti-tumor method and anti-tumor agent
US20090081209A1 (en) Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins
JP5486945B2 (ja) 新規腫瘍マーカーとしてのｇｐｉアンカー糖タンパク質ａｃａ
Seo et al. Expression of the Qa-2k phenotype encoded by the Q5k gene on the surface of tumor cells derived from H-2k mice.
AU2003213064B2 (en) Methods of therapy and diagnosis
Lieberman et al. A phosphorylated, disulfide-linked membrane protein in murine cytotoxic T lymphocytes.
Smith Expression, function and ligands for the Ly-49H NK cell activation receptor
Boscariol Studies on ovine CD4: genomic sequence analysis and protein cleavage studies with cathepsin proteases

Legal Events

Date Code Title Description
FZDE Discontinued